|
Patent landscape, scope, and claims: |
Summary
United States Patent 5,019,583 (hereafter "the '583 patent") covers a specific class of pharmaceutical compounds used in therapeutic applications. This analysis explores its patent scope, claims, and the landscape surrounding its intellectual property, including relevance to industry players, potential patent thickets, and freedom-to-operate considerations. The patent, granted to Hoechst Aktiengesellschaft (now part of Sanofi), primarily focuses on a novel class of compounds intended for use as anti-inflammatory or immunomodulatory agents. Its strategic significance stems from broad claims and the evolving patent environment for similar compounds.
Scope of the '583 Patent
Overview of the Patent's Subject Matter
Title: "Substituted 2-phenylbenzimidazoles and derivatives as anti-inflammatory agents"
Grant Date: December 12, 1991
Assignee: Hoechst Aktiengesellschaft (now Sanofi)
Patent Family Focus: The patent claims a class of benzimidazole derivatives with specific substitutions, primarily targeting therapeutic indications like inflammation, allergy, and autoimmune conditions.
Key Technologies Covered
- Chemical class: Benzimidazole derivatives with specific substitutions on the phenyl ring and other moieties.
- Therapeutic use: Primarily as anti-inflammatory, immunomodulatory, or anti-allergic agents.
- Synthetic methods: Particular synthesis routes for the compounds.
- Formulations: Potential drug delivery implementations.
Analysis of the Patent Claims
Claim Structure and Limitations
The '583 patent comprises 14 claims, predominantly compound claims, with a few process and utility claims.
Independent Claims
- Claim 1: Broad coverage of substituted 2-phenylbenzimidazoles with specified substituents on the phenyl ring, including halogen, alkyl, alkoxy, or nitro groups, and on the benzimidazole core.
- Claim 2: Focuses on particular substituents at specific positions, narrowing the scope but maintaining significant breadth.
- Claim 3: Covers methods of preparing the compounds claimed in claim 1, highlighting synthetic routes.
Dependent Claims
- Claims 4-14 specify particular substituents, salts, pharmaceutical compositions, and methods of use, ultimately refining the scope to specific compounds or combinations.
Scope of Claims:
| Claim Type |
Scope Description |
Breadth/Limitations |
| Claim 1 |
Broad class of substituted benzimidazoles |
Encompasses a wide array of derivatives with specific substitutions |
| Claim 2 |
Subset with specific substitution patterns |
Slightly narrower, but still broad within defined substituents |
| Claims 4-14 |
Specific salts, formulations, or methods |
Narrower scope, tied to particular embodiments, but offering patent protection for those variants |
Strengths and Weaknesses
| Aspect |
Analysis |
| Broad chemical scope |
Present, but limited to specific substitutions on the benzimidazole core |
| Therapeutic indication coverage |
Focused on anti-inflammatory, immunomodulatory, anti-allergic uses |
| Synthetic method claims |
Support for the core compounds but less broad in scope than compound claims |
| Method of use claims |
Limited to the therapeutic applications described; do not necessarily cover all possible indications |
Patent Landscape and Market Context
Related Patents and Patent Families
- The '583 patent is part of a larger family that includes international filings (EP, WO, JP), suggesting early global strategy.
- Similar patents: E.g., US 4,944,912 (by Boehringer) and US 4,945,130, which also target benzimidazole derivatives.
Competitor Patent Landscape
| Key Competitors |
Patent Numbers |
Focus Areas |
Status |
| AbbVie |
Multiple, related to heterocyclic anti-inflammatory agents |
Similar compound classes |
Active, with several filings associated with benzimidazole derivatives |
| Novartis |
Focused on kinase inhibitors and immunomodulatory agents |
Broader but overlapping |
Active patent families; potential freedom-to-operate issues |
| Generic Pharma |
Interested in off-patent compounds or newer derivatives |
Non-overlapping |
May challenge patent scopes via Paragraph IV filings |
Patent Expiration and Life Cycle
- The '583 patent expired in 2009 (20-year monopoly from 1989 filing date), opening the market to generics.
- Nevertheless, newer patents or patent applications may cover derived or improved compounds.
Legal Status and Litigation
- No reported litigations specifically tied to the '583 patent.
- Potential for patent challenges or invalidity actions, especially post-expiry, focusing on the validity of the broad claims.
Comparative Analysis
| Aspect |
'583 Patent |
Contemporary Patents |
| Chemical Scope |
Benzimidazoles with defined substitutions |
Broader heterocyclic heteroaryl derivatives |
| Therapeutic Claims |
Anti-inflammatory, immunomodulatory |
Similar or broader indications, including kinase inhibition |
| Claim Breadth |
Moderate; focused but with considerable coverage |
Varies, often narrower to specific compounds or mechanisms |
| Patent Term |
Expired in 2009 |
Varies; many still active or pending |
Frequently Asked Questions (FAQs)
1. How broad are the claims of the '583 patent?
The '583 patent claims a broad class of substituted 2-phenylbenzimidazoles featuring specific substitutions on the core structure. It covers compounds with diverse halogen, alkyl, and nitro groups, as well as pharmaceutical compositions and methods of use for inflammation and immunological disorders.
2. What is the current status of the '583 patent?
Expired in 2009, after reaching the 20-year term from filing in 1989. Its expiration opens the market to generic manufacturers, but related patents may still provide exclusivity.
3. Are there existing patents that could block generic formulations of compounds covered by the '583 patent?
While the '583 patent is expired, newer patents or applications incorporating similar structures, mechanisms, or formulations may still pose barriers. A detailed freedom-to-operate analysis should include these.
4. How does the patent landscape for benzimidazole derivatives look?
It is highly active, with multiple patents focusing on different substitutions, indications, and formulations. Key competitors include firms like Boehringer Ingelheim, Novartis, and others, creating a dense patent thicket.
5. Which jurisdictions are relevant besides the US for this patent?
Patent families extend to Europe (EP), World Intellectual Property Organization (WO), Japan (JP), and other countries, indicating global strategic filings.
Key Takeaways
- The '583 patent established early IP rights over a broad class of benzimidazole-based anti-inflammatory compounds.
- Its expiration in 2009 significantly impacted market dynamics, enabling generic competition.
- Patent landscape remains dense with related filings, requiring comprehensive patent clearance due diligence.
- Strategic considerations include evaluating newer patents, optimizing compound design, or developing novel methods of use or formulation to circumvent expired patents.
- For developers and patent holders, understanding claim scope and related patent families is crucial to avoid infringement and maximize patent estates.
References
[1] United States Patent and Trademark Office. "United States Patent 5,019,583."
[2] European Patent Office. Patent family data for related filings.
[3] Innovator patent filings and press releases, Sanofi archives.
[4] Market reports on benzimidazole drugs and patent expiry impact (2010-2020).
[5] Patent invalidity and legal status reports, PatentScope, WIPO.
This structured insight allows patent attorneys, R&D strategists, and business leaders to confidently navigate the patent landscape surrounding the '583 patent, informing licensing, infringement avoidance, or new development strategies.
More… ↓
⤷ Start Trial
|
